| ID | 1358 |
| Name of the vaccine | SHAN6 |
| Microbe | Bacteria |
| Disease name | Haemophilus influenzae type b (Hib) |
| Name of bacteria | Haemophilus influenzae |
| Type of vaccine | Combination |
| Nucleic acid content | DNA |
| Age | 8 to 11 weeks |
| Description of the vaccine | DTwP-HepB-Hib-IPV hexavalent vaccine. |
| Name of the manufacturer | Sanofi Pasteur, a Sanofi Company |
| Name of the manufacturing country | Thailand |
| Year of manufacture | 2021 |
| Clinical Phase status | Clinical - Phase 3 |
| Bacterial strain | Anaerobic gram-negative coccobacillus. |
| Efficacy | NA |
| Vaccine formulation | Suspension for injection |
| Dosage | Three doses. |
| Mechanism of action | NA |
| Route of administration | Intramuscular |
| Indications | NA |
| Export | NA |
| Approval | NA |
| Adjuvant | NA |
| Repurposing | For whole cell pertussis, tetanus, hepatitis B, diphtheria and inactivated poliovirus. |
| Side effects of vaccine | NA |
| Post vaccination | NA |
| Dose type | Combination (3 doses) |
| Interspecies transfer | NA |
| PubMed identifier | NA |
| Clinical trial number | NCT04429295 |
| Reference | http://www.ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=30046&EncHid=&modid=&compid=%27,%2730046det%27 |
| Other name | NA |
| Additional Links | NA
|